News & Press Releases

All OrangeHook Salamander LifeMed ID

FOR IMMEDIATE RELEASE
Media Contact: Robert F. Riess, COO / CMO - OrangeHook, Inc.

InXite and OrangeHook Announce Strategic Relationship for the Healthcare Market

InXite Health Systems and OrangeHook, Inc. Launch “InXite Health OS”

Partners to Provide an Integrated Continuum of Care Solution for the Healthcare Market driven by chronic care management (CCM) program.

Columbus, Ohio and MINNEAPOLIS –October 19, 2017 – InXite Health Systems (“IHS”) a, Columbus, Ohio healthcare IT firm and OrangeHook, Inc.: OTCQB: ORHK (“OrangeHook”), a Wayzata, Minnesota software solutions company focused on identity solutions, announced today that they have reached an agreement forming a major strategic relationship for delivery of healthcare infrastructure solutions to the global healthcare market. The strategic product offerings will be based on each of the parties’ proprietary technologies, and will include a virtually integrated continuum of care platform powered by InXite’s advanced value-based care platform and OrangeHook’s patient identification and payments technologies. The bundled software solution uniquely empowers government agencies, payors, hospitals and healthcare providers to more effectively and cost-efficiently deliver patient-centered, value-based care and data-driven decision capabilities which are critical for improving patient outcomes, chronic care management, hospital readmissions and quality scores. The initial focus will be on providing CCM services approximately 2 million patients under managed services agreements with a variety of large health systems, Independent Physician Associations, State Healthcare Collaboratives, and Physician and Accountable Care Organizations across multiple states including Florida, Alabama, Ohio, West Virginia, Michigan, Arizona and California.

The comprehensive solution enables the data that is traditionally siloed within various hospital electronic medical records (EMR), practice management systems, pharmacy management systems and health plans to now be portable with the patient in a highly secure manner across the continuum of care. The solution will be branded by InXite as “InXite Health OS” (Health Operating System) and will deliver unparalleled capabilities that will transform the patient healthcare experience. InXite Health OS consists of advanced data interoperability, care coordination, patient engagement and quality reporting, and analytic capabilities from the InXite SmartCare Platform and leverages OrangeHook’s iChip® technology to power the “InXite Patient HealthCard.” OrangeHook’s patented iChip technology securely authenticates user access to unified patient information, will create an audit trail of patient encounters across the continuum of care and will provide “read and write” capabilities between the Patient HealthCard and the patients care team for easier and more effective exchange of information. The iChip will also provide the ability to deliver future capabilities to users such as advanced fraud protection and payment capabilities.

“The InXite/OrangeHook Health OS and Patient Health Card is analogous to the “ATM card for healthcare,” said James Paat, Chairman & CEO of InXite. “As healthcare is rapidly transforming from volume-based to value-based delivery and payment models, InXite Health OS provides the critical functionality needed to effectively and cost efficiently support value-based care programs including chronic care management, transition of care management and readmission and quality improvement initiatives.”

“Our strategic relationship and integrated solution is truly driven by customer demand in the healthcare market,” James L. Mandel, CEO of OrangeHook, Inc. stated. “Healthcare providers need comprehensive patient data to drive better patient outcomes and lower costs in a flexible and patient-centric manner, which are offered by the OrangeHook and InXite applications. We believe that the benefits of superior big data efficiency, artificial intelligence (“AI”), mobility, and built-in data protection that is compliant with healthcare standards are achieved only with the OrangeHook and InXite solutions. This comprehensive solution focuses on patient care within the scope of the healthcare driven continuum of care, provides both InXite and OrangeHook immediate revenue opportunities and applications that the market is already embracing.”

About InXite

InXite is a Columbus, Ohio-based healthcare innovation company. InXite executive personnel possess diverse experience across many vertical industries including financial services, supply chain management, national security & public safety, and healthcare. InXite has been recognized as one the 50 fastest growing healthcare technology companies in the US; as one of the 10 most disruptive technologies transforming healthcare; and as one of the most promising population health management companies of 2017. For more information please visit www.inxitehealth.com

About OrangeHook

OrangeHook Inc., is a global leader in identity solutions. Through its suite of proprietary technologies, OrangeHook helps health, government, and corporate entities with cloud, card and mobile based validation, accreditation, and verification services. OrangeHook’s solutions can be implemented quickly, and in a technologically agnostic manner. OrangeHook holds multiple patents and trademarks. OrangeHook solutions are HIPAA and HITECH compliant. For more information, visit www.orangehook.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1996 that represent OrangeHook management’s expectations or beliefs about future events relating to its planned joint venture with SCG. Forward-looking statements are identifiable by words such as “believe”, “intend”, “anticipate”, “expect”, “plan”, “will”, “may”, and other similar expressions. Forward-looking statements made in this presentation, which relate to OrangeHook’s agreement with InXite, involve known and unknown risks and uncertainties that may cause the actual results to differ materially from those expected and stated in this announcement. Actual results could differ if: i) the economy, and particularly the healthcare segments of the economy that impact the proposed relationship, does not grow and perform at least as well as forecast. In addition, actual results could differ as a result of, among other things, i) the expected immediate revenue as expected; ii) a lack of market acceptance of the integrated solution; iii) unanticipated technical or cost issues associated with integration of the parties’ solutions. It is not possible to foresee or identify all factors that could cause actual results to differ from expected results. As such, you should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potential inaccurate assumptions. For additional information on factors that could cause our actual results to differ and for more specific information about our business and the risks associated with it, please review the periodic reports that OrangeHook files publicly with the Securities and Exchange Commission. Forward-looking statements made herein speak only as to the date of this release and, except as expressly required by the securities laws, we undertake no obligation to publicly update any forward-looking statements made herein.

Contacts:
OrangeHook, Inc. - Jim Mandel, 612-504-3646, This email address is being protected from spambots. You need JavaScript enabled to view it.

InXite Health, Inc. - James Paat, 614-408-1680, This email address is being protected from spambots. You need JavaScript enabled to view it.

Sage Convalescence Gaiety and OrangeHook, Inc. Announce Terms to Enter China Healthcare Market

Link to Source

FOR IMMEDIATE RELEASE
Media Contact: Robert F. Riess, COO / CMO - OrangeHook, Inc.

Shanghai, China and MINNEAPOLIS June 28, 2017 (OTCIQ) -- Sage Convalescence Gaiety (“SCG”) a, Shanghai, China healthcare firm and OrangeHook, Inc. (OTCQB: ORHK) (“OrangeHook”), announced today that they have reached an agreement on material terms and executed a non-binding term sheet to form a joint venture based in Shanghai for the delivery of healthcare infrastructure solutions in the China healthcare market. The joint venture’s intended product offerings will be based on each of the parties’ proprietary technologies, and will include an SCG integrated “continuum of care” platform powered by OrangeHook’s patient identification and payments technologies. The to-be-named JV intends to offer bundled healthcare technology services to Chinese healthcare providers consisting of point of sale hardware solutions, state of the art smart cards, and mobile SIM card applications.

“We expect China’s healthcare providers and consumers will significantly benefit from OrangeHook’s solution offerings,” said Xian Feng, Chairman & CEO of SCG. “These high-performance systems are intended to reduce patient identification errors and related fraud issues, which has the potential to vastly reduce liabilities for Chinese healthcare providers and significantly improve patient care. These applications identify the patient with high reliability, creating interoperability efficiencies for China’s healthcare system and the 1.4 billion Chinese citizens who attend China’s healthcare facilities on average 5.5 times per year.”

“Our intended partnership and joint solution is truly driven by customer demand in the China market,” James L. Mandel, CEO of OrangeHook, Inc. stated. “Healthcare providers desire flexibility and performance quality, which are offered by the OrangeHook applications, as well as the superior data efficiency, mobility, and built-in data protection that is compliant with all healthcare standards, which we believe only OrangeHook solutions deliver. OrangeHook is excited about this planned relationship with SCG and the proven experience and background of the SCG management team.”

A key component of the term sheet calls for SCG to purchase between 500,000 and 2 million shares of OrangeHook’s common stock and/or payment of royalties depending on the timing and amount of the stock purchase. All equity purchases are to be based upon a valuation of a minimum of $20 per share. Closing of the transaction is subject to conditions including, among other things, completion of definitive agreements, board approvals, and possible regulatory approvals by both the United States and Chinese governments. Additional details of the transaction will be disclosed once a definitive agreement is executed.

SCG is a Shanghai, China-based healthcare IT Company. SCG’s executive personnel possess preeminent backgrounds and experience with companies such as General Electric Healthcare, Phillips Medical Systems, Stryker, DFJ Dragon Fund, Fosun Health Holdings, Private and Public China Healthcare Sectors. SCG has long-standing relationships with decision makers in the China healthcare market.

OrangeHook Inc., is a U.S.-based patient identity solution that automates patient validation, record matching, and overall registration workflow. By eliminating duplicate records and preventing patient misidentification, fraud, keystroke, and billing errors, patient safety, satisfaction, and care outcomes are significantly improved. OrangeHook accepts multiple patient identity tokens, including government, military or insurance ID cards, smart or magstripe cards, mobile devices (NFC), mobile SIM card applications, and state of-the-art biometrics solutions, including pre-existing and deployed biometric solutions, to authenticate patients and collect payment at all points of care. OrangeHook’s solutions can be implemented quickly, and in a technologically agnostic manner. OrangeHook holds multiple patents and trademarks. OrangeHook is HIPAA and HITECH compliant. For more information, visit www.orangehook.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that represent OrangeHook management’s expectations or beliefs about future events relating to its planned joint venture with SCG. Forward-looking statements are identifiable by words such as “believe”, “intend”, “anticipate”, “expect”, “plan”, “will”, “may”, and other similar expressions. Forward-looking statements made in this press release, which relate to OrangeHook’s proposed agreement and planned joint venture with SCG, involve known and unknown risks and uncertainties that may cause the actual results to differ materially from those expected and stated in this announcement. Actual results could differ if the Chinese economy, and particularly the healthcare segments of the Chinese economy that impact the proposed JV’s business, does not grow and perform at least as well as forecast. In addition, actual results could differ as a result of, among other things, (i) the parties’ inability to reach a definitive agreement based on the term sheet, (ii) a failure of any closing condition in the definitive agreement to occur or be waived, (iii) a lack of market acceptance for the JV’s product offerings or any inability or undue delay in bringing those product offerings to market, (iv) any non-compliance or inability to comply with Chinese corporate or healthcare laws or U.S. laws governing foreign investment or foreign business practices and (iv) any inability on the part of either party to continue to finance the JV or its own operations. It is not possible to foresee or identify all factors that could cause actual results to differ from expected results. As such, you should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potential inaccurate assumptions nor should you place undue reliance on any forward-looking statements contained in this press release. For additional information on factors that could cause our actual results to differ and for more specific information about our business and the risks associated with it, please review the periodic reports that OrangeHook files publicly with the Securities and Exchange Commission. Forward-looking statements made herein speak only as to the date of this press release and, except as expressly required by the securities laws, we undertake no obligation to publicly update any forward-looking statements made herein.


Contacts:

OrangeHook, Inc. James Mandel, CEO This email address is being protected from spambots. You need JavaScript enabled to view it.

More...

On April 06, 2017, OrangeHook updated its stock symmbol from NUVL to ORHK.

See stock information

FOR IMMEDIATE RELEASE
Media Contact: Robert F. Riess, COO / CMO - OrangeHook, Inc.

MINNEAPOLIS, March 14, 2017 (GLOBE NEWSWIRE) -- Through a recently signed Agreement between Medsis, a U.S. based big data company, and the Colombian Government’s National Victims Repair Unit, an initiative was launched to modernize the entire Colombian citizens database system by means of the donation of Medsis’ big data management technology platform, CEREBRO, and OrangeHook resources. The system will convert all existing databases into a single unified civil registry. The use of CEREBRO, along with advanced state-of-the-art security protocols and algorithms, will allow identities of all registered victims to be safely verified and stored, creating efficiencies in all programs within the National Victims Repair Unit and potentially beyond. The National Victims Repair Unit was created to facilitate reparation payments which are a key component of the Colombian Government’s recent peace agreement with the FARC in their efforts to achieve a conclusion of the country’s 60-year-old internal conflict.

The project will provide a platform for the distribution of benefits to more than 8 million identified victims. Under terms of the agreement payments of approximately 1.2 Trillion Colombian Pesos ($400 Million USD) will be distributed annually over the next ten years, over 12 trillion pesos ($4B USD) in total.

WAIV, an Australian company focused on payment applications, will be the financial bridge between the National Victims Repair Unit and the persons registered in it. Together with a known payment network for the WAIVCARD and the participation of a Colombian bank, WAIV will be responsible for integrating the MEDSIS: CEREBRO platform to accurately disburse the reparations and financial humanitarian aid to the people registered in the database. The integration with WAIV as a processor makes possible the accurate and timely procedure to manage and disburse the funds to the victims over the next 10 years.

DAX CABRERA, President and CEO of Medsis stated, “This historic project, to help heal the nation of Colombia, is exactly what Medsis was designed for. The vision of Colombia and of director ALAN JARA to provide humanitarian aid throughout Colombia, is an important global goal of Medsis.”

John Fenga, CEO of WAIV, expressed his satisfaction at being part of this initiative that will allow relief to victims of Colombia's unfortunate internal conflict, “We’re excited to be a part of this incredible opportunity,” said Fenga, “Helping the less fortunate is a key part of the WAIV philosophy.”

OrangeHook, a Minneapolis, Minnesota-based company, is an identification authentication company with systems and applications focused in healthcare, government, and data transfer accuracy.

James Mandel, OrangeHook CEO, stated, “We are delighted to be recognized as a leader in identification processes, and look forward to our continuing involvement in this historic program.”

For more information about OrangeHook, please visit www.orangehook.com.


About the players:

The Victims Unit (UnidadVictimas.gov.co) is a branch of the Colombian Government whose objective is to help and integrally repair the victims of war, with the objective of completing social inclusion and reparation of all affected victims.

Medsis (Medsis.com) is an international information technology company that provides platforms for data management, integration, consolidation, and analysis. Their systems are designed to operate in environments with volatile infrastructure such as remote, rural, and conflict areas.

WAIV (WAIVCard.com) is an international technology company offering a comprehensive payment system designed to make banking online safer, faster, and cheaper. Its aim is to increase global financial inclusion for the 2 billion unbanked people worldwide.

OrangeHook (orangehook.com) (OTC:NUVLD) is a global leader in identity solutions. Through its suite of proprietary technologies, OrangeHook helps health, government, and corporate entities with cloud-based validation, accreditation, and verification services.


Contacts:

OrangeHook, Inc. James Mandel, CEO This email address is being protected from spambots. You need JavaScript enabled to view it.

Medsis Sara Cabrera This email address is being protected from spambots. You need JavaScript enabled to view it.

WAIV John Fenga, CEO This email address is being protected from spambots. You need JavaScript enabled to view it.

More...

On March 8, 2017, Medsis released a press release on OrangeHook, titled "Medsis Donates Solution to the Government of Colombia for the Reparation of Victims".

Read more

FOR IMMEDIATE RELEASE
Media Contact: Robert F. Riess, COO / CMO - OrangeHook, Inc.

-Upon completion, combined company will be an SEC reporting, publicly traded and fully integrated SaaS-based conglomerate of disruptive technology solutions centered on healthcare, big data, safety, and banking
-Transaction designed to establish public company platform that adds the OrangeHook suite of product and service offerings to Nuvel’s existing operations, substantially reduce Nuvel’s existing debt and preserve value opportunity for existing Nuvel shareholders

LOS GATOS, Calif. and MINNEAPOLIS, July 13, 2016 (GLOBE NEWSWIRE) -- Nuvel Holdings, Inc. (OTC PINK:NUVL) has entered into a definitive merger agreement with OrangeHook, Inc., of Minneapolis, Minnesota, a privately-held Software as a Service (SaaS) conglomerate. Upon closing of the transaction, the combined company will be fully reporting and publicly-traded and will consist of five operating entities that use complementary proprietary technology to offer disruptive and potentially life-changing applications centered on healthcare, big-data, safety and banking.

The material terms of the agreement are summarized in a Current Report on Form 8-K of Nuvel filed with the Securities and Exchange Commission on Friday, July 8, 2016. In the transaction, Nuvel will issue shares of two new classes of preferred stock to OrangeHook shareholders in exchange for all of OrangeHook’s preferred and common stock. Following the merger, Nuvel will effect a reverse split of its common stock, after which the preferred shares issued in the merger to OrangeHook’s common shareholders will convert into one share of common stock in the combined company for each share of OrangeHook common stock held immediately prior to the merger, and a substantial majority of Nuvel’s existing debt will be exchanged for equity in the combined company.

The existing shareholders of Nuvel will have the opportunity to participate in ongoing growth opportunities in the combined company. Such shareholders who hold Nuvel common stock immediately after closing of the merger (or a record date declared shortly thereafter), will be eligible to receive up to an aggregate of 357,143 shares of Nuvel common stock on a pro-rata basis if the Nuvel, Inc. operating entity achieves a $1.5 million revenue milestone, as measured and within the timeframes specified in the agreement. Based on current projections, management of the combined company is optimistic about the achievement of the earn-out milestone.

For purposes of structuring the transaction, the parties used an assumed $14 per share valuation for OrangeHook’s common stock, which is the same valuation that OrangeHook used to structure the prior acquisitions of its other portfolio companies. Based on the assumed $14 per share valuation of OrangeHook common stock, the value of these prior transactions totaled approximately $53.2 million. This assumed valuation of OrangeHook common stock was arbitrarily determined based upon pro-forma financial projections of OrangeHook management and there exists no quantifiable valuation analysis to support the same, aside from internal projections based upon existing contracts of the combined companies, among other factors.

Following the merger, the combined company will change its name to OrangeHook and plans to trade under a yet to be determined OrangeHook-related trading symbol. The combined company will immediately encompass the expanded offerings of the OrangeHook portfolio within the newly formed and recapitalized company. Subsequent to the merger, the combined company plans to apply for listing on a national securities exchange as soon as reasonably practical.

Rick Resnick, Nuvel’s CEO, commented, “This transaction allows Nuvel to more freely move forward as a result of the elimination of the vast majority of our current debt, which we believe positions the company for substantial growth and stability. We believe the transaction offers a fair exchange for existing Nuvel common shareholders through the participation in a future earn-out distribution based on a revenue milestone we are confident of achieving.”

James Mandel, OrangeHook CEO, commented, “We are very pleased to achieve the next step in our company’s evolution, which sets the stage for the public launch of our suite of disruptive and potentially life-changing applications designed to change the world we live in for the better in areas including mobile payments, healthcare information, billing and payments, data compression and storage, and emergency responder coordination. Although we acknowledge that we are setting a high bar with our operating goals, we strongly believe that customer acceptance of our solutions and the real world need for the same will validate our optimism. We expect the coordinated and sophisticated deployment of our product and service offerings will create substantial value for existing OrangeHook and Nuvel shareholders, as well as future investors.”

Subject to satisfaction or waiver of closing conditions set forth in the merger agreement, the parties expect to close on the merger portion of the transaction in August 2016 and to effect the post-merger reverse split recapitalization to be completed by approximately Labor Day.

About Nuvel

Nuvel Holdings, Inc. seeks to engage in the business of designing, developing and selling a family of proxy and other appliances, and related software and services that secure, accelerate and optimize the delivery of business applications, Web content and other information to distributed users over private Enterprise networks, or across an enterprise's gateway to the public Internet.

About OrangeHook

OrangeHook is a holding company that accelerates the growth of selective and unique consumer, business, and governmental software applications which have the ability, in our opinion, to change the world we live in to be a better and safer place concentrating in the fields of safety, medicine, data acceleration, and banking. More at http://www.orangehook.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for certain forward-looking statements. Certain statements in this press release, including statements regarding the proposed merger between OrangeHook and Nuvel, the anticipated recapitalization, the value proposition of the transaction for existing Nuvel shareholders, targeted future revenue amounts for Nuvel, Inc. and operating results for the combined company, the anticipated completion dates for the merger and reverse split, and the assumed valuation for OrangeHook common stock (and the corresponding aggregate value of OrangeHook’s prior acquisitions), are forward-looking in nature. These statements are based on current expectations and intentions, as well as assumptions and estimates that management believed to be credible and reasonable but that are also subject to risks and uncertainties that may cause outcomes to differ from what is expected, including risks that the merger will not close in a timely manner or at all, or that the combined companies’ operating results will not meet management’s expectations.

For additional information regarding this transaction please contact the following:

Rick Resnick, CEO, Nuvel Holdings, Inc. @ This email address is being protected from spambots. You need JavaScript enabled to view it.

James Mandel, CEO, OrangeHook, Inc. @ This email address is being protected from spambots. You need JavaScript enabled to view it.

OrangeHook media contact: Robert F. Riess, Chief Marketing Officer @ This email address is being protected from spambots. You need JavaScript enabled to view it.

More...
FOR IMMEDIATE RELEASE
May 2015
Media Contact: Robert F. Riess, COO / CMO - OrangeHook, Inc.

Diverse Perspectives, Experiences and Skillsets Make OrangeHook, Inc. an Employer of Distinction
Leveraging a diverse array of skills and experience, OrangeHook, Inc. utilizes its Global Mindset to build creative solutions and bridge enterprises in exciting new ways aimed towards generating strong revenue growth, implementing operational efficiencies and creating synergies.

Wayzata, MN. Thought leaders across the technology economy take note: a new player is in town. OrangeHook, Inc., a technology holding company focused upon turbocharging disruptive software solutions, brings a wide breadth of industry and management experience, as well as an array of diverse backgrounds and cultural insights to bear on a market that is traditionally defined by its intensive specialization.

Allowing subject matter experts from a myriad of different backgrounds to work cohesively, interweaving years of experience, the latest technological breakthroughs and a solid foundation of analytical data leads OrangeHook to have a uniquely effective multifaceted approach to managing its holdings. Combining experts in the healthcare, network optimization, financial services and emergency management fields with decades of proven business leadership experience, OrangeHook’s hybrid approach to leadership highlights opportunities and synergies that otherwise would have gone unrecognized.

“We accept and appreciate a wide variety of different cultures,” says James Mandel, Chief Executive Officer of OrangeHook, Inc. “Not only do we accept and appreciate differences in ethnicity, race, age, sexual orientation, gender and religion, but we also greatly appreciate the beliefs, attitudes, values, life experiences and unique interests shared by our colleagues in the technology industry. By encouraging this type of diversity and seeking varied inputs, we are able to see a wide array of viewpoints and can utilize that awareness to create novel solutions and build bridges across seemingly insurmountable gaps, all while maximizing the resultant positive effects on the bottom line.”

Investors and business owners interested in learning more about OrangeHook and its portfolio companies are invited to visit our website at orangehook.com.

About OrangeHook, Inc.
OrangeHook, Inc. is a holding company focusing on companies with SaaS solutions that need additional assistance to impact the world today. Through its portfolio companies, OrangeHook accelerates a selective collection of consumer, business, and governmental software applications which meet the primary criteria of “changing the world we live in to be a better and safer place.” More at http://www.orangehook.com.
More...
Agilivant Names James L. Mandel as CEO.
Read more

Forward-Looking Statements

Certain statements made in this website, including but not limited to press releases or other written statements and statements in the Company’s SEC filings which are not statements of historical or current facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identifiable by words such as “believe”, “intend”, “anticipate”, “expect”, “plan”, “will”, “may”, and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of the Company to differ materially from the results or performance expressed or implied by such forward-looking statements. These forward-looking statements include statements expressing the intent, belief or current expectations of the Company and members of our management team and are based on current information we assessed when the statements were made and which by its nature is dynamic and subject to change. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date these statements were made. It is not possible to foresee or identify all factors, risks and uncertainties that could cause actual results to differ from expected results. As such, you should not consider any list of such factors to be an exhaustive statement of all risks, uncertainties or potential inaccurate assumptions. For additional information on factors that could cause our actual results to differ and for more specific information about our business and the risks associated with it, please review the periodic and current reports that we file publicly with the Securities and Exchange Commission.

Go to top